热门资讯> 正文
艾伯维的Rinvoq获得了溃疡性结肠炎、克罗恩病的更新适应症
2025-10-13 23:23
- AbbVie (NYSE:ABBV) said that the US FDA has updated the indication for its JAK inhibitor Rinvoq (upadacitinib) to allow individuals with ulcerative colitis or Crohn's disease to be given the treatment after having received at least one approved systemic therapy in the event TNF blockers are clinically inadvisable.
- Prior, the indication for ulcerative colitis and Crohn's was for those with an inadequate response or intolerance to one or more TNF blockers.
More on AbbVie
- AbbVie: Wins Accumulating While We Wait For Next BD Steps
- AbbVie For Healthy Dividend Growth
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- Short bets on S&P 500 Healthcare sector rises marginally to 1.91% in September; MRNA remains most shorted stock
- AbbVie succeeds in mid-stage study of Botox for essential tremor
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
